[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Brcić L, Vuletić LB, Stepan J, Bonevski A, Jakovljević G, Gasparov S, Marjanović K, Seiwerth S: Mast-cell sarcoma of the tibia. J Clin Pathol; 2007 Apr;60(4):424-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mast-cell sarcoma of a bone is described here for the first time.
  • The tumour presented in a 4-year-old boy, with pain, oedema and deformation of his right lower leg.
  • The cytoplasm around them was eosinophilic with many basophilic and toluidine-blue-positive granules.
  • The primary disease quickly progressed to mast-cell leukaemia, and despite intensive chemotherapy the patient died 18 months after first symptoms.
  • [MeSH-minor] Child, Preschool. Disease Progression. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Jul;25(7):603-25 [11377686.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):1013-9 [12826896.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):596-602 [3088063.001]
  • [Cites] Mod Pathol. 1999 Jul;12(7):739-43 [10430280.001]
  • [CommentIn] J Clin Pathol. 2011 Nov;64(11):1035-7 [21778298.001]
  • (PMID = 17405977.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2001118
  •  go-up   go-down


2. Maruo T, Namikawa K, Kunihiro A, Lynch J, Shida T, Kishikawa S: Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog. J S Afr Vet Assoc; 2009 Dec;80(4):261-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog.
  • A 10-year-old castrated male Golden retriever, weighing 36.3 kg was referred for evaluation owing to a decline in general condition.
  • Findings from the complete blood count revealed a marked lymphocytosis (113000/ml).
  • Examination of Wright-Giemsa-stained films of peripheral blood revealed the presence of large granular lymphocytes (LGL).
  • Seventy-two per cent (81360/ml) of the lymphocytes were found to be 12-17 microm in diameter, containing nuclei with mature clumped chromatin and abundant lightly basophilic cytoplasm with a variable number of fine azurophilic granules.
  • Based on these findings this case was diagnosed as LGL leukaemia.
  • As a result of multiple-agent chemotherapy, the markedly elevated levels of lymphocytes gradually decreased to 7500/ml on day 122 and the patient maintained a good quality of life for the following 3 months.
  • However, on around day 237, a soft, raised, bosselated mass on the labial region was noted.
  • Shortly after diagnosis, the dog developed sudden onset of central nervous system signs and died on day 270.
  • A common outcome of canine LGL is the development of acute blast crisis or lymphoma.
  • However, this case was notable for complication with histiocytic sarcoma from another origin.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Histiocytic Sarcoma / veterinary. Leukemia, Large Granular Lymphocytic / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dog Diseases. Dogs. Fatal Outcome. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458870.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Lee JH, Kim JW, Ko NY, Mun SH, Kim DK, Kim JD, Kim HS, Lee KR, Kim YK, Radinger M, Her E, Choi WS: Camellia japonica suppresses immunoglobulin E-mediated allergic response by the inhibition of Syk kinase activation in mast cells. Clin Exp Allergy; 2008 May;38(5):794-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Novel approaches are being explored to develop new therapies for various allergic diseases.
  • Complementary and alternative medicines are considered to be promising avenues for the development of such new therapies.
  • MATERIALS AND METHODS: The anti-allergic activity was tested by evaluating effects on degranulation of mast cells in culture and passive cutaneous anaphylaxis (PCA) in vivo.
  • Its mechanism of action was investigated by immunoblotting analysis, immunoprecipitation, RT-PCR, and other molecular biological approaches in mast cells.
  • RESULTS: We screened approximately 100 natural plant extracts collected in Korea for in vitro anti-allergic activity.
  • The leaf extract of Camellia japonica (LECJ) exhibited the most potent effect on degranulation in antigen-stimulated rodent and human mast cells.
  • LECJ reversibly inhibited degranulation in a dose-dependent manner, with IC(50) values of approximately 50 microg/mL for the mast cells, and it also suppressed the expression and secretion of TNF-alpha and IL-4 in rat basophilic leukaemia-2H3 mast cells.
  • In agreement with its in vitro activity, LECJ significantly inhibited mast cell-mediated PCA in an animal model.
  • LECJ inhibited activating phosphorylation of tyrosine Y371 on Syk kinase, indicating that LECJ inhibits the activity of Src-family kinases in mast cells.
  • In high-performance liquid chromatography analysis, quercetin-3-beta-D-glucoside and eugenol were identified as the major active components.
  • CONCLUSION: The present results strongly suggest that the anti-allergic activity of LECJ is mediated through inhibiting degranulation and allergic cytokine secretion by inhibition of Src-family kinase in mast cells and it may be useful for the treatment of mast cell-related immediate and delayed allergic diseases.
  • [MeSH-major] Camellia / chemistry. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Mast Cells / drug effects. Plant Extracts / pharmacology. Plant Leaves / chemistry. Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Basophils. Cell Degranulation. Cells, Cultured. Enzyme Activation. Humans. Hypersensitivity, Delayed / drug therapy. Hypersensitivity, Immediate / drug therapy. Immunoblotting. Immunoglobulin E / immunology. Immunoprecipitation. Korea. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Passive Cutaneous Anaphylaxis. Rats. Reverse Transcriptase Polymerase Chain Reaction. src-Family Kinases / antagonists & inhibitors

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Allergy. 2008 May;38(5):704-8 [18325033.001]
  • (PMID = 18261158.001).
  • [ISSN] 1365-2222
  • [Journal-full-title] Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • [ISO-abbreviation] Clin. Exp. Allergy
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Plant Extracts; 37341-29-0 / Immunoglobulin E; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


Advertisement
4. Knipping K, van Esch EC, Wijering SC, van der Heide S, Dubois AE, Garssen J: In vitro and in vivo anti-allergic effects of Arctium lappa L. Exp Biol Med (Maywood); 2008 Nov;233(11):1469-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discovery of drugs that can be used for the treatment of allergic disease is important in human health.
  • AL was selected out of 10,000 herbal extracts in a set-up for high throughput screening in which the degree of degranulation was monitored by the release of beta-hexosaminidase from rat basophil leukemia (RBL-2H3) cells.
  • The AL extract significantly reduced degranulation and biosynthesis of cys-leukotrienes of human basophils in peripheral blood mono-nuclear cells (PBMCs) (50% inhibitory concentration [IC(50)] = 8.3 and 11.4 microg/ml, respectively).
  • Viability and metabolic activity of the PBMCs were not affected.
  • Although arctiin, the active component of AL that has been described in the literature, was not able to reduce degranulation in RBL-2H3 cells, a single high-performance liquid chromatography (HPLC) fraction from the AL extract inhibited beta-hexosaminidase release (IC(50) = 22.2 microg/ml).
  • In addition, this active component was able to inhibit acute skin response in mice in vivo, indicating that AL is a very promising natural component for use in anti-allergic treatment.
  • [MeSH-minor] Animals. Basophil Degranulation Test. Basophils / drug effects. Basophils / metabolism. Chemical Fractionation. Chromatography, High Pressure Liquid. Ear Diseases / chemically induced. Ear Diseases / drug therapy. Edema / chemically induced. Edema / drug therapy. Humans. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Leukotrienes / biosynthesis. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703753.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Anti-Inflammatory Agents; 0 / Leukotrienes; 0 / Plant Extracts
  •  go-up   go-down


5. Baroody FM, Naclerio RM: Antiallergic effects of H1-receptor antagonists. Allergy; 2000;55 Suppl 64:17-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells.
  • This notion is supported by the fact that structurally unrelated drugs antagonize the H1-receptor and provide clinical benefit.
  • However, H1-receptor antagonism may not be their sole mechanism of action in treating allergic rhinitis.
  • On the basis of in vitro and animal experiments, drugs classified as H1-receptor antagonists have long been recognized to have additional pharmacological properties.
  • These additional properties are not uniformly distributed among drugs classified as H1-receptor antagonists.
  • In human challenge models, terfenadine, azatadine, and loratadine reduce IgE-mediated histamine release.
  • Cetirizine reduces eosinophilic infiltration at the site of antigen challenge in the skin, but not the nose.
  • In a nasal antigen challenge model, cetirizine pretreatment did not affect the levels of histamine and prostaglandin D2 recovered in postchallenge lavages, whereas the levels of albumin, N-tosyl-L-arginine methyl ester (TAME) esterase activity, and LTs were reduced.
  • In animal models, mizolastine inhibits antigen-induced eosinophil infiltration into mouse skin and into the nasal cavity of guinea-pigs.
  • Mizolastine also significantly inhibits antigen-induced neutrophil infiltration into the bronchoalveolar lavage fluids of guinea-pigs.
  • In addition, it inhibits arachidonic acid-induced paw oedema in rats without affecting carrageenin-induced rat paw oedema, suggesting an effect on LT generation.
  • In man, mizolastine inhibits early and late antigen-induced soluble intercellular adhesion molecule 1 (ICAM-1) levels in skin blisters.
  • It also inhibits anaphylactic release of histamine from rodent mast cells, LTC4 and LTB4 release from mouse bone-marrow-derived mast cells, LTC4 release from rat intestinal mast cells, and 5-lipoxygenase activity of polymorphonuclear neutrophils of guinea-pig intestines and rat basophilic leukaemia cells.
  • It is equally clear that these antiallergic effects are not uniformly shared among all drugs of this class.
  • The assessment of the clinical significance of these results and research regarding the parts of the molecules responsible for these activities are underway.
  • [MeSH-major] Anti-Allergic Agents / immunology. Histamine H1 Antagonists / immunology. Histamine H1 Antagonists / therapeutic use. Hypersensitivity / drug therapy. Hypersensitivity / immunology
  • [MeSH-minor] Animals. Benzimidazoles / immunology. Benzimidazoles / therapeutic use. Disease Models, Animal. Humans. Receptors, Histamine H1 / immunology. Rhinitis / drug therapy. Rhinitis / immunology

  • MedlinePlus Health Information. consumer health - Allergy.
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291777.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI45583; United States / NIDCD NIH HHS / DC / DC 02714
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Benzimidazoles; 0 / Histamine H1 Antagonists; 0 / Receptors, Histamine H1; 244O1F90NA / mizolastine
  • [Number-of-references] 34
  •  go-up   go-down


6. Masamoto Y, Nannya Y, Arai S, Koike Y, Hangaishi A, Yatomi Y, Kurokawa M: Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy. Br J Haematol; 2009 Mar;144(5):798-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Basophils / pathology. Leukemia, Promyelocytic, Acute / pathology. Oxides / therapeutic use
  • [MeSH-minor] Cell Differentiation / drug effects. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036092.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


7. Zhou J, Liu DF, Liu C, Kang ZM, Shen XH, Chen YZ, Xu T, Jiang CL: Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy; 2008 Sep;63(9):1177-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous report had shown that GCs could inhibit allergic asthma within 10 min, which the classical mechanism could not explain.
  • Using whole-cell patch clamp and fluorometric assay, we examined GCs' nongenomic effect on IgE-mediated exocytosis and histamine release of rat basophilic leukaemia-2H3 mast cells.
  • RESULTS: Inhaled GCs significantly inhibited airway mast cells degranulation in the allergic asthma model of guinea pigs within 10 min.
  • We further demonstrated that GCs' nongenomic effect was not through direct action on secretory machinery, but was mediated by a reduction in the [Ca(2+)](i) elevation.
  • CONCLUSIONS: The study suggested for the first time that nongenomic pathway was involved in GCs' rapid inhibition on allergic asthma, and raised the possibility of new therapeutic strategies for allergic diseases including asthma.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Cell Degranulation / drug effects. Glucocorticoids / pharmacology. Mast Cells / drug effects
  • [MeSH-minor] Animals. Asthma / drug therapy. Guinea Pigs. Histamine / metabolism. Male. Time Factors

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18699934.001).
  • [ISSN] 1398-9995
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 820484N8I3 / Histamine
  •  go-up   go-down






Advertisement